Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
Felicia Ceban, Joshua D. Rosenblat, Kevin Kratiuk, et al.
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 925-934
Closed Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 54
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 476-496
Closed Access | Times Cited: 45
History repeating: A roadmap to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
(2023)
Open Access | Times Cited: 23
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Jacob S. Aday, Brian S. Barnett, Dan Grossman, et al.
Psychedelic Medicine (2023) Vol. 1, Iss. 3, pp. 150-165
Closed Access | Times Cited: 22
The treatment of depression — searching for new ideas
Katarzyna Stachowicz, Magdalena Sowa-Kućma
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 33
A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis
Qiuwen Li, Saiying Wang, Xi Mei
Psychiatry Research (2022) Vol. 310, pp. 114396-114396
Closed Access | Times Cited: 30
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1547-1560
Open Access | Times Cited: 18
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis
Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira, et al.
Journal of Affective Disorders (2023) Vol. 330, pp. 227-238
Open Access | Times Cited: 14
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Eficácia da cetamina e esketamina no tratamento da depressão: revisão das evidências e perspectivas futuras
RAPHAELA NOGUEIRA DUTRA, Mario Vitor Ferreira Nascimento, João Pedro Silva Gontijo, et al.
STUDIES IN HEALTH SCIENCES (2025) Vol. 6, Iss. 1, pp. e14206-e14206
Closed Access
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002–2019
Claire Walsh, Ofir Livne, Dvora Shmulewitz, et al.
Addictive Behaviors Reports (2022) Vol. 16, pp. 100454-100454
Open Access | Times Cited: 21
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
Haoning Guo, Bin Wang, Shuying Yuan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Seltorexant for major depressive disorder
Kyle Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials
Bilal Abu-Hussein, Amr Elrosasy, Haidy Samy, et al.
Clinical & Translational Oncology (2025)
Closed Access
The neuroscientific basis of post-traumatic stress disorder (PTSD): From brain to treatment
Lila Agbaria, Foad Mirzaei, Nathalie Omar A'amar, et al.
Progress in brain research (2025)
Closed Access
Psychiatric disorders associated with PCSK9 inhibitors: A real‐world, pharmacovigilance study
Zhifang Deng, Jue Liu, Hongjian Gong, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 30, Iss. 4
Open Access | Times Cited: 10
The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway
Jiafang Wang, Yankun Feng, Qi Zhong, et al.
Open Life Sciences (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen Wen, Wenjing Zhao, Xing Xia, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 242, pp. 173773-173773
Closed Access | Times Cited: 3
Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs
Qinghua Guo, L. B. Guo, Wang Yong, et al.
Psychiatry Research (2024) Vol. 339, pp. 116018-116018
Closed Access | Times Cited: 3
Blood pressure changes during ketamine infusion for the treatment of depression
Mina Ansari, Brian Pittman, Daniel S. Tylee, et al.
General Hospital Psychiatry (2024) Vol. 90, pp. 62-67
Closed Access | Times Cited: 3
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Aistė Lengvenytė, Robertas Strumila, Émilie Olié, et al.
European Neuropsychopharmacology (2022) Vol. 57, pp. 88-104
Open Access | Times Cited: 15
Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review
Shiryn D. Sukhram, Grozdena Yilmaz, Jianying Gu
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 15
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Nicolas Garel, Jessica Drury, Julien Thibault Lévesque, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top